About this trial
The goal of this clinical trial is to learn if using an incentive spirometer can reduce lung problems in people with advanced lung cancer who are receiving chemotherapy and radiation therapy. The main questions the study aims to answer are:
Does using an incentive spirometer lower the chances of developing lung inflammation (pneumonitis)? Does it improve overall survival and quality of life?
Participants will:
Use an incentive spirometer, a device that helps with deep breathing, 10 times every hour while awake.
Continue using the spirometer daily during treatment and for up to three months after treatment.
Complete quality of life assessments at the start of the study and at 3, 6, and 12 months.
Researchers will compare the results to see if the incentive spirometer helps reduce lung problems and improves participants\' well-being during and after their cancer treatment.
Eligibility criteria
Qualifiers
Confirmed diagnosis of advanced non-small-cell lung cancer
Performance status (ECOG 0-1)
Eligible for concurrent chemotherapy and radiation
18 years or older
Disqualifiers
Previous lung or thoracic surgery
Enrollment in another pulmonary intervention trial
Home oxygen usage prior to enrolment
Radiological evidence of pleural effusion, pneumothorax, bullous emphysema, - or pneumonitis on staging imaging
Trial design
Treatments tested in this trial
- incentive spirometry
Treatment groups
Sponsors and collaborators
The Cooper Health System
Lead sponsor
The Cooper Foundation
Collaborator